Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Patients: Updated Results From XPORT-MF-034
Andrew Kuykendall, MD, highlights the potential of selinexor plus ruxolitinib in JAK inhibitor-naïve patients with MF based on promising response rates in XPORT-MF-034 updated results, with plans for a phase 3 study. He also noted the need to manage nausea as a adverse effect.
EP: 1.How JAK Inhibitors Have Shaped the Landscape of MF
EP: 2.Pelabresib Plus Ruxolitinib for JAK Inhibitor-Naïve Patients: Data From MANIFEST and MANIFEST-2
EP: 3.Navitoclax Plus Ruxolitinib for Untreated MF: Data From TRANSFORM-1
EP: 4.Navtemadlin Plus Ruxolitinib for Patients With MF who had Suboptimal Responses to Ruxolitinib
Now Viewing
EP: 5.Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Patients: Updated Results From XPORT-MF-034
EP: 6.Luspatercept With or Without Ruxolitinib for the Treatment of Anemia in Patients With MF: Data From ACE-536-MF-001
EP: 7.Future Directions in Combination Therapies for Myelofibrosis
EP: 8.Key Efficacy and Safety Takeaways From Recent Data on JAK Inhibitors for MF
EP: 9.The FREEDOM-2 Trial: Efficacy and Safety of Fedratinib in Patients With MF Previously Treated With Ruxolitinib
EP: 10.Selection and Sequencing of JAK Inhibitors for Patients With MF
EP: 11.Individualizing Therapy Goals for Patients With Myelofibrosis
EP: 12.Emerging Treatments for Myelofibrosis
Related Videos
Related Content
